Premium
Groundbreaking smoking cessation study highlights safety of varenicline, bupropion
Publication year - 2016
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30158
Subject(s) - varenicline , bupropion , smoking cessation , medicine , nicotine replacement therapy , food and drug administration , placebo , pharmacotherapy , adverse effect , nicotine , drug , clinical trial , pharmacology , psychiatry , alternative medicine , pathology
The largest‐ever trial of pharmacotherapy for smoking cessation, requested of two drug manufacturers by the Food and Drug Administration (FDA), has found no significant increase in neuropsychiatric adverse events from varenicline or bupropion compared with nicotine replacement therapy or placebo. The findings likely will intensify the discussion of whether regulators in the United States and other countries should revisit boxed warnings on the two smoking cessation treatments. Study results were published online April 22 in The Lancet .